Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses by Barrett, J, Belij-Rammerstorfer, S, Dold, C, Ewer, KJ, Folegatti, PM, Gilbride, C, Halkerston, R, Hill, J, Jenkin, D, Stockdale, L, Verheul, MK, Aley, PK, Angus, B, Bellamy, D, Berrie, E, Bibi, S, Bittaye, M, Carroll, MW, Cavell, B, Clutterbuck, EA, Edwards, N, Flaxman, A, Fuskova, M, Gorringe, A, Hallis, B, Kerridge, S, Lawrie, AM, Linder, A, Liu, X, Madhavan, M, Makinson, R, Mellors, J, Minassian, A, Moore, M, Mujadidi, Y, Plested, E, Poulton, I, Ramasamy, MN, Robinson, H, Rollier, CS, Song, R, Snape, MD, Tarrant, R, Taylor, S, Thomas, KM, Voysey, M, Watson, MEE, Wright, D, Douglas, AD, Green, CM, Hill, AVS, Lambe, T, Pollard, AJ